Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445440 | 0.94 | ALOX15 (0.49) | KMT2ABRD4ALOX15P2RY12HDAC1 | |
| SCHEMBL443046 | 0.92 | MAPT (0.48) | KMT2ABRD4P2RY12MAPTL3MBTL1 | |
| SCHEMBL4254739 | 0.91 | BRD4 (0.49) | KMT2ABRD4ALOX15P2RY12MAPT | |
| Dimethylamine SCHEMBL443672 | 0.89 | P2RY12 (0.52) | KMT2ABRD4P2RY12MAPTL3MBTL1 | |
| SCHEMBL443671 | 0.88 | HDAC6 (0.51) | P2RY12MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL443686 | 0.87 | MAPT (0.52) | KMT2AMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL445820 | 0.86 | MAPT (0.46) | P2RY12MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL31389187 | 0.84 | HDAC1 (0.61) | KMT2AALOX15P2RY12L3MBTL1HDAC1 | |
| SCHEMBL4258468 | 0.84 | MAPT (0.46) | KMT2ABRD4P2RY12MAPTL3MBTL1 | |
| SCHEMBL23710419 | 0.84 | ALOX15 (0.64) | ALOX15P2RY12RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140341989-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | LES LABORATOIRES SERVIER SAS (FR) | 2014-11-20 | — | — | US | claimed |
| EP-2755648-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | Pharmacyclics, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039488-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| US-20190184196-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10105552-B2 | Formulations of histone deacetylase inhibitor and uses thereof | PHARMACYCLICS LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170333731-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9492423-B2 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | PHARMACYCLICS LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-9403032-B2 | Formulations of histone deacetylase inhibitor and uses therof | PHARMACYCLICS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150335609-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF | PHARMACYCLICS LLC | 2015-11-26 | — | — | US | disclosed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2006042035-A2 | METHOD OF MONITORING ANTI-TUMOR ACTIVITY OF AN HDAC INHIBITOR | PHARMACYCLICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | KMT2A 90/4885BRD4 139/4885ALOX15 3440/4885 |
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | KMT2A 51/4885BRD4 67/4885ALOX15 4704/4885 |
| US-20170333731-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | KMT2A 51/4885BRD4 67/4885ALOX15 4704/4885 |
| US-20140341989-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | HDAC5, HDAC7, HDAC4 | KMT2A 26/4885BRD4 54/4885ALOX15 4801/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | KMT2A 249/4885BRD4 28/4885ALOX15 1903/4885 |
| US-10105552-B2 | Formulations of histone deacetylase inhibitor and uses thereof | HDAC1, HDAC7, HDAC5 | KMT2A 51/4885BRD4 67/4885ALOX15 4704/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | KMT2A 263/4885BRD4 166/4885ALOX15 3353/4885 |
| US-20150335609-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF | HDAC3, HDAC5, HDAC4 | KMT2A 43/4885BRD4 161/4885ALOX15 4317/4885 |
| US-20190184196-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | KMT2A 51/4885BRD4 67/4885ALOX15 4704/4885 |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | KMT2A 90/4885BRD4 139/4885ALOX15 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.